Kymera Therapeutics
KYMR
254 hedge funds and large institutions have $6.99B invested in Kymera Therapeutics in 2025 Q4 according to their latest regulatory filings, with 68 funds opening new positions, 97 increasing their positions, 64 reducing their positions, and 16 closing their positions.
325% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 16
53% more capital invested
Capital invested by funds: $4.58B → $6.99B (+$2.41B)
52% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 64
21% more funds holding
Funds holding: 210 → 254 (+44)
11.78% more ownership
Funds ownership: 113.1% → 124.88% (+12%)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
41% less call options, than puts
Call options by funds: $9.18M | Put options by funds: $15.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$206M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$135M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$76M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$71.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$52.9M |
| 2 |
Jennison Associates
New York
|
-$35.9M |
| 3 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$29.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$21.7M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$16.4M |
KYMR Hedge Fund Activity: Q4 2025 in Review
254 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q4 2025, worth a combined $6.99B — up 53% from $4.58B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new KYMR positions and 16 closed out — a net gain of 52 holders — while 97 added to existing stakes and 64 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $206M. The largest seller was Wellington Management Group, cutting an estimated $52.9M.
- 254 institutional investors held Kymera Therapeutics (KYMR) as of Q4 2025, up from 210 in Q3 2025.
- Funds reported $6.99B of Kymera Therapeutics stock for Q4 2025, up 53% quarter-over-quarter.
- 68 funds opened new Kymera Therapeutics positions in Q4 2025 and 16 closed out, a net change of +52 holders.
- The largest Kymera Therapeutics buyer in Q4 2025 was Fidelity Investments, an estimated $206M added.
- The largest Kymera Therapeutics seller in Q4 2025 was Wellington Management Group, an estimated $52.9M sold.
Based on aggregated 13F filings for Q4 2025.